indomethacin has been researched along with Mouth Neoplasms in 11 studies
Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.
indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.
Mouth Neoplasms: Tumors or cancer of the MOUTH.
| Excerpt | Relevance | Reference |
|---|---|---|
| " No statistically significant difference in delayed hypersensitivity response to dinitrochlorobenzene was found between indomethacin-treated, tumor-bearing and control groups." | 3.67 | Indomethacin and 7,12-dimethylbenz(a)anthracene-induced carcinogenesis in the hamster buccal pouch. ( Gould, AR; Grant, FT; Miller, RL; Perry, DA, 1985) |
| "In this study, we used an oral squamous cell carcinoma cell line to study growth inhibition and changes in critical cell cycle-regulating proteins induced by the selective COX-2 inhibitor celecoxib." | 1.32 | Selective inhibition of cyclooxygenase 2 induces p27kip1 and skp2 in oral squamous cell carcinoma. ( Chau, M; Gilbert, R; Jordan, RC; Lim, MS; Lim, S; Mäkitie, AA; Viani, MA, 2003) |
| "All 5 cell lines constantly showed growth suppression with positive dosage effect of indomethacin." | 1.31 | In vitro growth inhibition by indomethacin on human oral squamous cell carcinoma lines synergistically suppressed by all-trans retinoic acid correlating to apoptosis. ( Chang, RC; Kao, SY; Tu, SF; Wu, CH; Yang, CC, 2002) |
| "The results demonstrate that human oral squamous carcinoma cell lines produce an immunosuppressive factor that may have a role in tumour evasion of the host immune response." | 1.28 | Production of a suppressor of lymphocyte proliferation by two human oral carcinoma cell lines. ( Crane, IJ; Prime, SS; Rice, SQ; Scully, C, 1992) |
| " Indomethacin, in the dosage administered, was not found to cause regression of established tumors." | 1.27 | The effect of indomethacin on tumor regression in DMBA-induced epithelial neoplasia of hamster cheek pouch mucosa. ( Craig, GT; Franklin, CD, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (36.36) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 5 (45.45) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Wolf, GT | 1 |
| Liu, S | 1 |
| Bellile, E | 1 |
| Sartor, M | 1 |
| Rozek, L | 1 |
| Thomas, D | 1 |
| Nguyen, A | 1 |
| Zarins, K | 1 |
| McHugh, JB | 1 |
| Yang, CC | 1 |
| Tu, SF | 1 |
| Wu, CH | 1 |
| Chang, RC | 1 |
| Kao, SY | 1 |
| Mäkitie, AA | 1 |
| Chau, M | 1 |
| Lim, S | 1 |
| Viani, MA | 1 |
| Gilbert, R | 1 |
| Lim, MS | 1 |
| Jordan, RC | 1 |
| Tímár, J | 2 |
| Forster-Horváth, C | 2 |
| Lukits, J | 2 |
| Döme, B | 2 |
| Ladányi, A | 2 |
| Remenár, E | 2 |
| Kásler, M | 2 |
| Bencsik, M | 1 |
| Répássy, G | 2 |
| Szabó, G | 2 |
| Velich, N | 2 |
| Suba, Z | 2 |
| Elõ, J | 2 |
| Balatoni, Z | 2 |
| Bajtai, A | 1 |
| Chretien, P | 2 |
| Talor, E | 2 |
| Kuo, CL | 1 |
| Chi, CW | 1 |
| Liu, TY | 1 |
| Godény, M | 1 |
| Bencsik, B | 1 |
| Pócza, K | 1 |
| Zemplén, B | 1 |
| Perkins, TM | 1 |
| Shklar, G | 1 |
| Rice, SQ | 1 |
| Crane, IJ | 1 |
| Scully, C | 1 |
| Prime, SS | 1 |
| Franklin, CD | 1 |
| Craig, GT | 1 |
| Pillsbury, HC | 1 |
| Webster, WP | 1 |
| Rosenman, J | 1 |
| Gould, AR | 1 |
| Miller, RL | 1 |
| Grant, FT | 1 |
| Perry, DA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Phase 2 Trial of Neoadjuvant and Adjuvant Therapy With the IRX 2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity[NCT02609386] | Phase 2 | 105 participants (Actual) | Interventional | 2015-12-31 | Completed | ||
| Radiosensitization With a COX-2 Inhibitor (Celecoxib), With Chemoradiation for Cancer of the Head and Neck[NCT00581971] | Phase 1/Phase 2 | 30 participants (Actual) | Interventional | 2002-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Evaluate the response to concurrent celecoxib, carboplatin, paclitaxel, and radiotherapy in the treatment of locally advanced SSC of the head and neck. Response is determined by local control only, local and distant metastasis, distant metastasis only, second primary, and surgical salvage. (NCT00581971)
Timeframe: 2 years from end of treatment (Radiation therapy)
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| Local Control Only | Local Control and Distant Metastasis | Distant Metastatsis Only | Secondary Primary - Site Unknown | Surgical Salvage | |
| Recurrence | 6 | 2 | 1 | 2 | 3 |
Particpants experiencing Acute Toxicities > Grade 3 (NCT00581971)
Timeframe: 2 years from radiation therapy
| Intervention | participants (Number) | ||
|---|---|---|---|
| Hematologic | Dermatitis | Mucositis/Dysphagia | |
| Acute Toxicity | 12 | 7 | 16 |
4 trials available for indomethacin and Mouth Neoplasms
| Article | Year |
|---|---|
Tumor infiltrating lymphocytes after neoadjuvant IRX-2 immunotherapy in oral squamous cell carcinoma: Interim findings from the INSPIRE trial.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Antineoplastic Agents, Alkylating; B7-H1 | 2020 |
The effect of leukocyte interleukin injection (Multikine) treatment on the peritumoral and intratumoral subpopulation of mononuclear cells and on tumor epithelia: a possible new approach to augmenting sensitivity to radiation therapy and chemotherapy in o
Topics: Adjuvants, Immunologic; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chem | 2003 |
Neoadjuvant immunotherapy of oral squamous cell carcinoma modulates intratumoral CD4/CD8 ratio and tumor microenvironment: a multicenter phase II clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Biopsy, Needle; Carcinoma, Squamous Cell; CD4-CD8 Ratio; Cyclophosph | 2005 |
Prostaglandin inhibitor and radiotherapy in advanced head and neck cancers.
Topics: Clinical Trials as Topic; Combined Modality Therapy; Double-Blind Method; Head and Neck Neoplasms; H | 1986 |
7 other studies available for indomethacin and Mouth Neoplasms
| Article | Year |
|---|---|
In vitro growth inhibition by indomethacin on human oral squamous cell carcinoma lines synergistically suppressed by all-trans retinoic acid correlating to apoptosis.
Topics: Apoptosis; Carcinoma, Squamous Cell; Drug Synergism; Humans; Immunohistochemistry; Indomethacin; Mou | 2002 |
Selective inhibition of cyclooxygenase 2 induces p27kip1 and skp2 in oral squamous cell carcinoma.
Topics: Carcinoma, Squamous Cell; Celecoxib; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Surviva | 2003 |
The anti-inflammatory potential of berberine in vitro and in vivo.
Topics: Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Berberine; Blotting, Wes | 2004 |
Delay in hamster buccal pouch carcinogenesis by aspirin and indomethacin.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Administration, Oral; Animals; Aspirin; Carcinoma, Squamous Cell; | 1982 |
Production of a suppressor of lymphocyte proliferation by two human oral carcinoma cell lines.
Topics: Carcinoma, Squamous Cell; Cell Line; Chromatography, Gel; Culture Media; Dose-Response Relationship, | 1992 |
The effect of indomethacin on tumor regression in DMBA-induced epithelial neoplasia of hamster cheek pouch mucosa.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Cheek; Cricetinae; Indomethacin; Lymph Nodes; Male; Mesoc | 1987 |
Indomethacin and 7,12-dimethylbenz(a)anthracene-induced carcinogenesis in the hamster buccal pouch.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Carcinoma; Cheek; Cricetinae; Dinitrochlorobenzene; Drug | 1985 |